The incidence of Cushing's disease: a nationwide Swedish study.
Cushing’s syndrome
Epidemiology
Incidence
Validation
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
pubmed:
26
2
2019
medline:
18
6
2019
entrez:
26
2
2019
Statut:
ppublish
Résumé
Studies on the incidence of Cushing's disease (CD) are few and usually limited by a small number of patients. The aim of this study was to assess the annual incidence in a nationwide cohort of patients with presumed CD in Sweden. Patients registered with a diagnostic code for Cushing's syndrome (CS) or CD, between 1987 and 2013 were identified in the Swedish National Patient Registry. The CD diagnosis was validated by reviewing clinical, biochemical, imaging, and histopathological data. Of 1317 patients identified, 534 (41%) had confirmed CD. One-hundred-and-fifty-six (12%) patients had other forms of CS, 41 (3%) had probable but unconfirmed CD, and 334 (25%) had diagnoses unrelated to CS. The mean (95% confidence interval) annual incidence between 1987 and 2013 of confirmed CD was 1.6 (1.4-1.8) cases per million. 1987-1995, 1996-2004, and 2005-2013, the mean annual incidence was 1.5 (1.1-1.8), 1.4 (1.0-1.7) and 2.0 (1.7-2.3) cases per million, respectively. During the last time period the incidence was higher than during the first and second time periods (P < 0.05). The incidence of CD in Sweden (1.6 cases per million) is in agreement with most previous reports. A higher incidence between 2005 and 2013 compared to 1987-2004 was noticed. Whether this reflects a truly increased incidence of the disease, or simply an increased awareness, earlier recognition, and earlier diagnosis can, however, not be answered. This study also illustrates the importance of validation of the diagnosis of CD in epidemiological research.
Sections du résumé
BACKGROUND
BACKGROUND
Studies on the incidence of Cushing's disease (CD) are few and usually limited by a small number of patients. The aim of this study was to assess the annual incidence in a nationwide cohort of patients with presumed CD in Sweden.
METHODS
METHODS
Patients registered with a diagnostic code for Cushing's syndrome (CS) or CD, between 1987 and 2013 were identified in the Swedish National Patient Registry. The CD diagnosis was validated by reviewing clinical, biochemical, imaging, and histopathological data.
RESULTS
RESULTS
Of 1317 patients identified, 534 (41%) had confirmed CD. One-hundred-and-fifty-six (12%) patients had other forms of CS, 41 (3%) had probable but unconfirmed CD, and 334 (25%) had diagnoses unrelated to CS. The mean (95% confidence interval) annual incidence between 1987 and 2013 of confirmed CD was 1.6 (1.4-1.8) cases per million. 1987-1995, 1996-2004, and 2005-2013, the mean annual incidence was 1.5 (1.1-1.8), 1.4 (1.0-1.7) and 2.0 (1.7-2.3) cases per million, respectively. During the last time period the incidence was higher than during the first and second time periods (P < 0.05).
CONCLUSION
CONCLUSIONS
The incidence of CD in Sweden (1.6 cases per million) is in agreement with most previous reports. A higher incidence between 2005 and 2013 compared to 1987-2004 was noticed. Whether this reflects a truly increased incidence of the disease, or simply an increased awareness, earlier recognition, and earlier diagnosis can, however, not be answered. This study also illustrates the importance of validation of the diagnosis of CD in epidemiological research.
Identifiants
pubmed: 30799512
doi: 10.1007/s11102-019-00951-1
pii: 10.1007/s11102-019-00951-1
pmc: PMC6418061
doi:
Substances chimiques
Adrenocorticotropic Hormone
9002-60-2
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-186Subventions
Organisme : Göteborgs Läkaresällskap (SE)
ID : NA
Références
J Intern Med. 1999 May;245(5):463-8
pubmed: 10363746
Ann Intern Med. 1999 May 18;130(10):821-4
pubmed: 10366371
Rheumatology (Oxford). 1999 Jul;38(7):668-74
pubmed: 10461483
Int J Cardiol. 2000 Oct;76(1):17-21
pubmed: 11121592
J Clin Endocrinol Metab. 2001 Jan;86(1):117-23
pubmed: 11231987
J Clin Endocrinol Metab. 2004 Dec;89(12):6348-57
pubmed: 15579802
J Clin Endocrinol Metab. 2006 Dec;91(12):4849-53
pubmed: 16968806
J Clin Endocrinol Metab. 2007 Mar;92(3):976-81
pubmed: 17200171
J Clin Endocrinol Metab. 2010 Sep;95(9):4268-75
pubmed: 20534753
Clin Endocrinol (Oxf). 2011 Jun;74(6):792-3
pubmed: 21175734
J Clin Endocrinol Metab. 2011 Mar;96(3):632-42
pubmed: 21193542
J Clin Epidemiol. 2011 Oct;64(10):1118-26
pubmed: 21463925
Clin Endocrinol (Oxf). 2011 Oct;75(4):436-42
pubmed: 21609352
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
J Clin Endocrinol Metab. 2012 Apr;97(4):1194-201
pubmed: 22278423
Eur J Endocrinol. 2013 Oct 08;169(5):715-23
pubmed: 23996696
Pituitary. 2015 Jun;18(3):283-9
pubmed: 24803324
Eur J Endocrinol. 2014 Oct;171(4):519-26
pubmed: 25084775
J Clin Endocrinol Metab. 2015 Feb;100(2):467-74
pubmed: 25375987
Eur J Endocrinol. 2015 Apr;172(4):R143-9
pubmed: 25722097
J Clin Endocrinol Metab. 2015 Jul;100(7):2651-8
pubmed: 25946030
Lancet Diabetes Endocrinol. 2016 Jul;4(7):569-76
pubmed: 27265184
Clin Endocrinol (Oxf). 1994 Apr;40(4):479-84
pubmed: 8187313
BMJ. 1998 Jun 20;316(7148):1858-63
pubmed: 9632404